AIM ImmunoTech's Vital Presentation at the SITC Meeting
OCALA, Fla. - AIM ImmunoTech Inc. (NYSE American: AIM) recently garnered attention with the acceptance of their research on a groundbreaking clinical trial at the Society for Immunotherapy of Cancer (SITC) meeting. This major event, taking place at National Harbor, Maryland, from November 5-9, highlights significant advancements in cancer treatment research.
Details of the Accepted Abstract
The abstract titled "A Phase II Trial of Combination Locoregional Chemoimmunotherapy in Recurrent Platinum-Sensitive Ovarian Cancer Triggers a T Lymphotactic Response Correlating with Clinical Outcomes" will be presented by Dr. Mackenzy M. Radolec, a Clinical Assistant Professor at UPMC Magee-Women’s Hospital. This trial addresses the pressing issue of cisplatin-resistant advanced recurrent ovarian cancer, an area where treatment options have been notably limited.
Key Presentation Information
Details of the poster presentation include:
- Abstract Number: 1343
- Date: November 7, 2025
- Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center
Significance of the Findings
Ampligen® (rintatolimod), the lead product of AIM ImmunoTech, is a promising therapeutic option being studied as a treatment for multiple cancers, including ovarian cancer. This presentation marks a pivotal step for AIM as it seeks to showcase its innovative approach to therapy, leveraging the unique properties of Ampligen® to enhance patient outcomes significantly.
What is Ampligen®?
Ampligen® is a first-in-class investigational drug designed to act on specific immune targets. As a highly selective TLR3 agonist and double-stranded RNA immunomodulator, it demonstrates broad-spectrum activity against various cancers and viral diseases. Currently, AIM ImmunoTech is engaged in extensive clinical trials to explore its efficacy across different medical areas.
Company Overview
AIM ImmunoTech Inc. is dedicated to developing therapeutics that battle not just cancer but also viral diseases and immune disorders. They utilize advanced scientific principles to pioneer treatments that may transform patient lives. This commitment to research is reflected in their ongoing projects and collaborations.
Connecting with AIM ImmunoTech
For more information regarding AIM ImmunoTech and their ongoing initiatives, interested parties can visit their official website or follow their social media accounts for the latest updates. Engaging with the company helps to understand its impact in the evolving landscape of cancer research and treatment.
Frequently Asked Questions
What is the significance of AIM ImmunoTech's presentation at the SITC?
The presentation highlights AIM ImmunoTech's innovative strategies for tackling ovarian cancer, a critical area in oncology.
Who is presenting the abstract?
Dr. Mackenzy M. Radolec, Clinical Assistant Professor at UPMC Magee-Women’s Hospital, will present the findings.
What is Ampligen®?
Ampligen® is an investigational drug that acts as a TLR3 agonist, targeting immune mechanisms to treat cancer and viral diseases.
When and where will the presentation take place?
The presentation is scheduled for November 7, 2025, at the Gaylord National Resort and Convention Center.
How can I learn more about AIM ImmunoTech?
You can visit AIM ImmunoTech's official website or follow them on social media for the latest updates and information regarding their research and therapies.
